secwatch.observer — SEC 8-K summary
======================================

Issuer:     Accelerate Diagnostics, Inc (—)
CIK:        0000727207
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001104659-24-041230
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Accelerate Diagnostics reports Q4 net loss $13M, full-year net loss $61.6M; Wave trials planned Q2 2024
--------------------------------------------------------------------------------

- Q4 net sales $3.0M flat YoY; full-year net sales $12.1M down 5% from $12.8M.
- Q4 gross margin 21% vs 28% YoY; full-year 21% vs 26%, including $1.2M inventory write-down.
- Q4 net loss $13.0M ($0.89/share); full-year net loss $61.6M ($4.94/share).
- Cash used Q4 $7.9M, full-year $46.3M; year-end cash $13.2M.
- Wave AST system clinical trials on track for Q2 2024; ~90% customer interest in adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/727207/000110465924041230/0001104659-24-041230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/727207/000110465924041230/tm2410254d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer